WallStreetZenWallStreetZen

NYSE: RDY
Dr Reddys Laboratories Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their RDY stock forecasts and price targets.

Forecast return on equity

Is RDY forecast to generate an efficient return?

Company
1,396.07%
Industry
285.9%
Market
228.26%
RDY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RDY forecast to generate an efficient return on assets?

Company
944.1%
Industry
157.31%
RDY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RDY earnings per share forecast

What is RDY's earnings per share in the next 3 years based on estimates from 41 analysts?

Avg 1 year Forecast
$63.73+7,925.97%
Avg 2 year Forecast
$57.13+7,094.7%
Avg 3 year Forecast
$64.86+8,069.31%
RDY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

RDY revenue forecast

What is RDY's revenue in the next 3 years based on estimates from 41 analysts?

Avg 1 year Forecast
$345.6B+8,972.04%
Avg 2 year Forecast
$354.4B+9,204.92%
Avg 3 year Forecast
$386.1B+10,034.86%
RDY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RDY earnings growth forecast

How is RDY forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
328.65%
Industry
366.35%
Market
42.76%
RDY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
RDY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
RDY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

RDY revenue growth forecast

How is RDY forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
365.45%
Industry
132.91%
Market
25.81%
RDY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RDY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RDY vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
RDY$13.89N/AN/A
ELAN$21.69$22.83+5.27%Strong Buy
VTRS$11.09$15.00+35.26%Strong Buy
RGC$16.98N/AN/A
NBIX$154.99$179.29+15.68%Strong Buy
View Top Pharmaceutical Stocks

Dr Reddys Laboratories Stock Forecast FAQ

What is RDY's earnings growth forecast for 2026-2028?

(NYSE: RDY) Dr Reddys Laboratories's forecast annual earnings growth rate of 328.65% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 366.35%, and while it is forecast to beat the US market's average forecast earnings growth rate of 42.76%.

Dr Reddys Laboratories's earnings in 2025 is $657,564,833.On average, 41 Wall Street analysts forecast RDY's earnings for 2026 to be $53,176,669,481, with the lowest RDY earnings forecast at $43,991,735,833, and the highest RDY earnings forecast at $65,275,270,927. On average, 41 Wall Street analysts forecast RDY's earnings for 2027 to be $47,669,013,735, with the lowest RDY earnings forecast at $34,264,406,198, and the highest RDY earnings forecast at $60,631,526,821.

In 2028, RDY is forecast to generate $54,126,363,132 in earnings, with the lowest earnings forecast at $39,661,663,498 and the highest earnings forecast at $71,846,606,927.

If you're new to stock investing, here's how to buy Dr Reddys Laboratories stock.

What is RDY's revenue growth forecast for 2026-2028?

(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 365.45% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.91%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.81%.

Dr Reddys Laboratories's revenue in 2025 is $3,785,730,898.On average, 41 Wall Street analysts forecast RDY's revenue for 2026 to be $288,365,243,849,145, with the lowest RDY revenue forecast at $238,736,011,015,770, and the highest RDY revenue forecast at $326,551,590,262,275. On average, 41 Wall Street analysts forecast RDY's revenue for 2027 to be $295,767,697,392,060, with the lowest RDY revenue forecast at $259,231,903,690,900, and the highest RDY revenue forecast at $328,342,331,475,565.

In 2028, RDY is forecast to generate $322,148,169,301,170 in revenue, with the lowest revenue forecast at $281,311,592,648,800 and the highest revenue forecast at $366,635,488,175,415.

What is RDY's forecast return on assets (ROA) for 2026-2028?

(NYSE: RDY) forecast ROA is 944.1%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 157.31%.

What is RDY's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: RDY) Dr Reddys Laboratories's current Earnings Per Share (EPS) is $0.79. On average, analysts forecast that RDY's EPS will be $63.73 for 2026, with the lowest EPS forecast at $52.72, and the highest EPS forecast at $78.23. On average, analysts forecast that RDY's EPS will be $57.13 for 2027, with the lowest EPS forecast at $41.06, and the highest EPS forecast at $72.66. In 2028, RDY's EPS is forecast to hit $64.86 (min: $47.53, max: $86.10).

What is RDY's forecast return on equity (ROE) for 2026-2028?

(NYSE: RDY) forecast ROE is 1,396.07%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.